Immunome Inc
For the period ended Dec 31, 2023. Filed Mar 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 28, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
None.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on March 28, 2024.
| | | |
|---|---|---|
| | IMMUNOME, INC. | |
| | | |
| | By: | /s/ Clay B. Siegall Ph.D. |
| | | Name: Clay B. Siegall, Ph.D. |
| | | Title: President and Chief Executive Officer |
POWER OF ATTORNEY
KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Clay B. Siegall, Ph.D. and Max Rosett, and each of them, his true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him in his name, place and stead, in any and all capacities, to sign this report, and file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, full power and authority to do and perform each and every act and thing requisite and necessary to be done as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons in the capacities and on the dates indicated on behalf of the Registrant.
| | | | | |
|---|---|---|---|---|
| Signature | Title | Date | ||
| | | | | |
| | | | | |
| /s/ Clay B. Siegall Ph.D. | | President, Chief Executive Officer and Director | | March 28, 2024 |
| Clay B. Siegall Ph.D. | | (Principal Executive Officer) | | |
| | | | | |
| /s/ Max Rosett | | EVP, Operations and Interim Chief Financial Officer | | March 28, 2024 |
| Max Rosett | | (Principal Financial Officer) | | |
| | | | | |
| /S/ Bob Lapetina | | VP, Finance and Corporate Controller(Principal Accounting Officer) | | March 28, 2024 |
| Bob Lapetina | | | | |
| /s/ Isaac Barchas, J.D | | Director | | March 28, 2024 |
| Isaac Barchas, J.D | | | | |
| | | | | |
| /s/ Jean-Jacques Bienaime | | Director | | March 28, 2024 |
| Jean-Jacques Bienaime | | | | |
| | | | | |
| /s/ James Boylan | | Director | | March 28, 2024 |
| James Boylan. | | | | |
| | | | | |
| /s/ Carol Schafer | | Director | | March 28, 2024 |
| Carol Schafer | | | | |
| | | | | |
| /s/ Philip Wagenheim | | Director | | March 28, 2024 |
| Philip Wagenheim | | | | |
| | | | | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.